glp-1 drugs for insulin resistance One in 10 people may have to diabetes GLP-1 Agonists: A Comprehensive Overview

GLP-1 receptor agonist 7 generates cAMP under the mediation of GLP-1R with an EC50 of 0.2 nM

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic poly-peptide (GIP, previously known as gastric inhibitory polypeptide) are key incretin

with a GLP-1

However, further research is needed to fully understand how these therapies exert their effect on body weight and in the last section we cover open questions about the potential mechanisms of multiagonist drugs, and the understanding of how gutbrain communication can be leveraged to achieve sustained body weight loss without adverse effects.

Experts say more education and awareness are needed.

Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases